AeroVironment, Inc. (AVAV)
- 1Q27 Revenue: $480.5M, +5.7% YoY, beat estimates by $24.41M
- 1Q27 Non-GAAP EPS: $0.59, beat estimates by $0.34
- FY27 Guidance: Reaffirmed FY27 revenue guidance of US$2.125–2.225B, adjusted EBITDA of US$305–325M and adjusted EPS of US$3.02–3.34. The revenue midpoint of US$2.175B is broadly aligned with consensus of approximately US$2.19B, while the US$3.18 EPS midpoint is slightly below approximately US$3.22 consensus.
- Comment: This was a fundamentally solid quarter. Revenue and EPS both exceeded expectations, while the 1.4x book-to-bill and US$1.5B record funded backlog are more important than the relatively modest 6% reported revenue growth. Global defense spending remains structurally supportive, while AeroVironment has broadened materially beyond Switchblade and small UAS following BlueHalo into counter-UAS, directed energy, space and cyber. The backlog increase provides better visibility that current defense demand can translate into revenue over subsequent quarters. The key issue is the absence of a guidance raise and the quality of near-term earnings growth. Adjusted EBITDA actually declined slightly YoY despite higher revenue, indicating that BlueHalo integration, mix and investment spending are limiting operating leverage. FY27 adjusted EPS guidance also remains broadly in line to slightly below consensus. Given the stock’s very high sensitivity to defense contract announcements, investors need continued bookings growth and evidence that the enlarged portfolio can convert backlog into stronger margins rather than merely higher revenue. Shares initially rose more than 4% after the earnings release, but down roughly 5% in the latest regular session, suggesting investors remain cautious on guidance and execution despite the headline beat. The principal variables to monitor are funded backlog conversion, bookings and book-to-bill, Switchblade and counter-UAS orders, BlueHalo integration, Autonomous Systems margins, U.S./European defense budgets and any major programme awards. 2Q27 recommended trading range: $130 to $165. Neutral Outlook.
AeroVironment, Inc.（AVAV)
- 27财年第一季度营收：4.805亿美元，同比增长5.7%，超出预期2441万美元
- 27财年第一季度非公认会计准则每股收益：0.59美元，大幅超出预期0.34美元
- 27财年全年指引：重申全年营收指引为21.25亿–22.25亿美元，调整后EBITDA为3.05亿–3.25亿美元，调整后EPS为3.02–3.34美元；营收中值（21.75亿美元）与市场共识（约21.9亿美元）基本一致，而EPS中值（3.18美元）略低于市场共识的约3.22美元。
- 短评：本季度基本面表现稳健，营收与盈利双双超预期。但相较于6%的温和营收增速，1.4倍的订单出货比（book-to-bill）是更具前瞻意义的核心亮点，为后续季度的营收转化提供了极高的能见度。核心亮点：全球国防开支的持续增长为公司提供了结构性的宏观支撑。在成功收购BlueHalo之后，AeroVironment的业务版图已从单一的“弹簧刀”（Switchblade），大幅拓展至反无人机（counter-UAS）、定向能武器、太空及网络战领域，产品矩阵与抗风险能力显著增强。核心隐忧（指引保守与盈利质量）：市场最失望的点在于管理层并未借机上调全年指引，且短期盈利增长的质量有待提升。尽管营收实现增长，但调整后EBITDA同比实际上略有下滑，表明BlueHalo的并购整合成本、产品组合变化以及前期的资本投入，正在压制短期运营杠杆的释放。此外，略低于共识的EPS指引也引发了市场对其利润率修复节奏的担忧。市场反应：鉴于该股对国防合同公告的高度敏感性，资金对其实际交付能力要求苛刻。财报后股价盘初虽上涨超4%，但在随后的常规交易时段回落约5%，表明投资者在“表观超预期”与“平淡的指引”之间，依然选择了对执行力保持谨慎。后续关键变量包括：（1）已注资积压订单向实际营收的转化效率；（2）新增订单量与订单出货比的持续性；（3）“弹簧刀”及反无人机系统的军方采购节奏；（4）BlueHalo并购后的业务整合与协同效应显现；（5）自主系统（Autonomous Systems）；（6）美欧国防预算的落地情况；（7）重大军方项目的中标与合同签订。AeroVironment 凭借在巡飞弹与小型无人机领域的绝对领先地位，叠加BlueHalo带来的全方位防务能力扩充，已深度嵌入全球国防现代化与不对称作战的核心供应链。然而，并购整合期的利润率承压与相对保守的盈利指引，使得短期估值扩张受到压制，需等待利润率拐点的实质性确认。27财年第一季度建议交易区间：130美元至165美元。中性前景。
Nano-X Imaging Ltd. (NNOX)
- 2Q26 Revenue: $4.2M, +38.2% YoY, miss estimates by $1.19M
- 2Q26 GAAP EPS: –$0.79, miss estimates by $0.63
- 3Q26 Guidance: No explicit guidance from company
- Comment: This was a weak quarter despite the headline 37% revenue growth. There are some genuine commercialization milestones: Nanox expanded to 10 U.S. distribution partners, began scans and insurer reimbursement at its first Nanox Imaging Network site, added an ARC installation at a Florida orthopedic center and continues operating a system within RadNet. These developments provide evidence that the product has moved beyond pure regulatory-development stage into early commercial use. The key issue is that commercial conversion remains extremely slow relative to the original investment thesis. Imaging-system/OEM revenue was only about US$0.2M, management reported no meaningful increase in systems progressing through deployment, revenue missed consensus by roughly 23%, and the company has abandoned annual revenue guidance. The US$40.7M AI impairment is also a significant negative signal because it suggests management materially reduced the carrying value of assets that were previously expected to contribute to the company’s AI strategy. Meanwhile, non-GAAP losses continue exceeding US$11M per quarter against only US$4.2M of revenue. Shares fell approximately 17% to US$0.78 following the results, giving Nanox a market capitalization of only around US$45M. At this valuation, upside can be very large if ARC deployments suddenly accelerate, but conventional valuation metrics are effectively unusable because the company remains deeply loss-making and commercialization visibility is poor. The principal variables to monitor are actual installed and revenue-generating ARC systems, monthly scan utilization, reimbursement progress, system revenue rather than distribution agreements, cash burn, additional equity issuance and progress toward a sustainable gross profit. 3Q26 recommended trading range: $0.60 to $1.10. Negative Outlook.
Nano-X Imaging Ltd.（NNOX)
- 26财年第二季度营收：420万美元，同比增长38.2%，低于预期119万美元
- 26财年第二季度公认会计准则每股亏损（GAAP EPS）：-0.79美元，低于预期0.63美元（亏损显著扩大）
- 26财年第三季度指引：公司未提供明确的财务指引（已放弃提供年度营收指引）
- 短评：本季度表现疲软，尽管表观营收实现了超30%的增长，但商业化转化速度相较于最初的投资逻辑而言极其缓慢。早期商业化里程碑：公司取得了一些实质性的商业化进展，包括将美国分销合作伙伴扩展至10家、在首个Nanox Imaging Network站点正式启动扫描服务并实现保险报销、在佛罗里达州一家骨科中心新增ARC（Nanox.ARC）设备安装，并继续在RadNet网络内运营系统。这些迹象表明，其产品已跨越纯粹的监管与研发阶段，迈入早期商业化应用阶段。核心痛点（商业化迟缓与资产减值）：成像系统与OEM收入仅约20万美元，管理层表示正在部署的系统数量并未出现实质性增加，营收低于市场共识约23%。更严重的负面信号是高达4070万美元的AI资产减值，这表明管理层大幅下调了此前预期将为公司AI战略做出贡献的资产账面价值，战略前景受挫。此外，在营收仅为420万美元的情况下，单季非GAAP亏损仍超过1100万美元，烧钱速度依然严峻。市场反应：财报后股价大跌约17%至0.78美元，公司总市值缩水至仅约4500万美元。在这一极低的估值水位下，若ARC设备的部署能突然加速，股价将具备极大的向上弹性（类似深度价外期权）；但由于公司深陷亏损泥潭且商业化能见度极差，传统的估值模型已完全失效。后续关键变量包括：（1）实际安装并产生经常性收入的ARC系统数量；（2）月度扫描服务的使用率与单台设备产出；（3）医疗保险报销资质的审批与覆盖进展；（4）实质性的系统销售收入（而非仅仅是签署纸面分销协议）；（5）现金消耗率（Cash burn）；（6）后续融资需求与股权稀释风险。Nano-X 拥有颠覆传统医疗影像成本的底层技术愿景，但目前正面临严峻的“从技术到商业变现”的死亡之谷考验。极低的市值赋予了其极高的赔率与博弈价值，但在看到设备规模化部署与毛利转正的实质性证据前，基本面风险依然极高，不适合稳健型资金参与。26财年第三季度建议交易区间：0.60美元至1.10美元。负面前景。
